Semaglutide Cuts Asthma Attacks by Nearly 40%

Asthma Relief Emerges from Diabetes Drug

European researchers reported that semaglutide, the active component of Ozempic and Wegovy, cuts asthma attacks by nearly 40% in adults with moderate disease, based on a September 2026 study presented at a leading respiratory conference. The investigation enrolled more than 2,500 participants across five European nations with an average age of 45 years and both sexes.

Participants received a weekly subcutaneous injection of semaglutide for a year while researchers monitored emergency room visits, rescue inhaler use, and lung function tests. The medication’s anti‑inflammatory effect appears to reduce airway hyper‑responsiveness, leading to fewer severe exacerbations. No serious side effects were observed, and benefits were consistent across age groups and initial disease severity.

In the trial, participants receiving semaglutide experienced a 38% drop in the number of moderate or severe asthma attacks compared with the placebo group. Inhaler usage fell by 30%, indicating reduced symptom burden.

Dr. Elena Martínez, lead investigator of the study, noted that 'the consistent reduction in attacks across diverse patient cohorts suggests semaglutide may modify the underlying inflammatory pathways of asthma.'

Can a Weight‑Loss Drug Rewrite Asthma Management?

Clinicians noted that the drug could complement existing inhaled therapies, especially for patients struggling to control symptoms with standard inhalers alone.

Researchers measured sputum eosinophil counts and airway resistance before and after treatment, observing a 28% decline in eosinophils and a 15% improvement in bronchial hyper‑reactivity. These physiological changes align with the clinical reduction in attack frequency, suggesting semaglutide influences multiple pathways involved in asthma and may also reduce medication reliance in real‑world settings across diverse populations and ethnicities today.

Dr. Samuel Liu, a pulmonologist not involved in the trial, commented that 'semaglutide’s dual action on weight regulation and inflammation could open new therapeutic avenues, but clinicians will need robust long‑term safety data before widespread adoption.'

Frequently Asked Questions

Health officials are now considering adding semaglutide to asthma treatment guidelines, though insurers must weigh the drug’s high cost against potential savings from fewer emergency visits. Researchers plan larger, long‑term studies to confirm durability and assess real‑world effectiveness.

How much does semaglutide reduce asthma attacks? The study showed a 38% decrease in moderate or severe attacks compared with placebo. This equates to about one fewer attack per week for most patients.

Is semaglutide safe for asthma patients? No serious adverse events were reported in the trial, and the drug’s safety profile aligns with its established use for diabetes and weight management. However, long‑term monitoring is still required.

Can the drug replace inhalers? It is not intended to replace inhaled medications, but clinicians may use it as an adjunct to reduce overall attack frequency and medication reliance.